Subject to change.
Subject to change.
Dr. Larry Vaughan is currently Director of Scientific Affairs at BD. He previously held the position of Director of Research and Development, where he led molecular assay development. His team developed the BD Onclarity™ HPV Assay, which received U.S. PMA approval in February 2018, extended genotyping approval in 2020, and self-collection approval in 2024. This work culminated in a change in the ASCCP management guidelines to include extended genotyping and self-collection.
Join us for an exclusive look at a breakthrough cervical cytology implementation at Tyrolpath, Austria's largest private pathology laboratory. This pioneering lab transformed their high-volume pap smear processing workflow through the integration of Pramana's SpectralHT™ whole slide imaging scanner, BD's SurePath™ preparation, and the Techcyte SureView® Cervical Cytology System. Learn about their journey from traditional cytology to automated digital screening with AI-powered analysis, the challenges they overcame, and the remarkable results achieved. This session will showcase real-world implementation insights, operational benefits, and the future of cervical cancer screening through integrated digital solutions. Perfect for laboratory directors, cytology supervisors, and anyone interested in the digital transformation of pathology workflows. Techcyte, Pramana, and BD look forward to welcoming digital pathology leaders interested in learning more about this groundbreaking technology. BD (Becton, Dickinson and Company) is the exclusive global distributor of the Techcyte SureView ® Cervical Cytology System.